Charles Moore
Stock Analyst at Robert W. Baird
(2.99)
# 2,577
Out of 4,361 analysts
7
Total ratings
71.4%
Success rate
18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Moore
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNLI Denali Therapeutics | Maintained: Buy | $32 → $34 | $19.35 | +75.71% | 2 | Apr 7, 2026 | |
| CTNM Contineum Therapeutics | Maintained: Buy | $14 → $20 | $12.38 | +61.55% | 2 | Mar 6, 2026 | |
| CSE: DRUG Bright Minds Biosciences Inc. | Maintained: Buy | $196.08 → $173.98 | $106.82 | +62.88% | 3 | Feb 13, 2026 |
Denali Therapeutics
Apr 7, 2026
Maintained: Buy
Price Target: $32 → $34
Current: $19.35
Upside: +75.71%
Contineum Therapeutics
Mar 6, 2026
Maintained: Buy
Price Target: $14 → $20
Current: $12.38
Upside: +61.55%
Bright Minds Biosciences Inc.
Feb 13, 2026
Maintained: Buy
Price Target: $196.08 → $173.98
Current: $106.82
Upside: +62.88%